The role of dasatinib in the management of chronic myeloid leukemia
作者： Bao-An Chen , Runzhe Chen
DOI: 10.2147/DDDT.S80207
关键词:
摘要: Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for chronic, blastic, or accelerated phase chronic myeloid leukemia (CML) patients who are resistant intolerant to previous treatment. It potently inhibits BCR/ABL and SRC-family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK), as well c-KIT, PDGFR-a -b, ephrin receptor kinase. Various clinical trials have provided evidence that it has more durable complete hematologic cytogenetic responses, potency in imatinib-resistant -intolerant CML, also shown its advantages newly diagnosed CML compared imatinib. In this review, we mainly focus on the structure, mechanisms, pharmacokinetics, pharmacogenetics of dasatinib. We summarize with dasatinib provide our recommendations treatment CML.
sci-hub.se 参考文章(64)
Digisha Trivedi, Pamela Landsman-Blumberg, Theodore Darkow, David Smith, Donna McMorrow, C. Daniel Mullins, Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment Journal of managed care & specialty pharmacy. ,vol. 20, pp. 1006- 1015 ,(2014) , 10.18553/JMCP.2014.20.10.1006
Giuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, Tamas Masszi, Ricardo Pasquini, Frederic Maloisel, Philipp Erben, Jorge Cortes, Ronald Paquette, M. Brigid Bradley-Garelik, Chao Zhu, Herve Dombret, Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily Cancer. ,vol. 116, pp. 3852- 3861 ,(2010) , 10.1002/CNCR.25123
Lori A. Gardner, Jelena Klawitter, Mark A. Gregory, Vadym Zaberezhnyy, Dmitry Baturin, Daniel A. Pollyea, Naoko Takebe, Uwe Christians, Lia Gore, James DeGregori, Christopher C. Porter, Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia American Journal of Hematology. ,vol. 89, pp. 896- 903 ,(2014) , 10.1002/AJH.23776
Elias Jabbour, Jeffrey H. Lipton, A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clinical Lymphoma, Myeloma & Leukemia. ,vol. 13, pp. 646- 656 ,(2013) , 10.1016/J.CLML.2013.05.012
Hisashi Sakamaki, Ken-ichi Ishizawa, Masafumi Taniwaki, Shin Fujisawa, Yasuo Morishima, Kensei Tobinai, Masaya Okada, Kiyoshi Ando, Noriko Usui, Shuichi Miyawaki, Atae Utsunomiya, Nobuhiko Uoshima, Tadashi Nagai, Tomoki Naoe, Toshiko Motoji, Itsuro Jinnai, Mitsune Tanimoto, Yasushi Miyazaki, Kazunori Ohnishi, Shinsuke Iida, Shinichiro Okamoto, Taku Seriu, Ryuzo Ohno, Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology. ,vol. 89, pp. 332- 341 ,(2009) , 10.1007/S12185-009-0260-2
Krisztina Futosi, Tamás Németh, Robert Pick, Tibor Vántus, Barbara Walzog, Attila Mócsai, Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood. ,vol. 119, pp. 4981- 4991 ,(2012) , 10.1182/BLOOD-2011-07-369041
Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki, Saengsuree Jootar, Tadeusz Robak, Nina Khoroshko, Tamas Masszi, Aleksander Skotnicki, Andrzej Hellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena Countouriotis, Neil Shah, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. ,vol. 109, pp. 5143- 5150 ,(2007) , 10.1182/BLOOD-2006-11-056028
Neil P. Shah, Francis Y. Lee, Roger Luo, Yibin Jiang, Marjolein Donker, Cem Akin, Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis Blood. ,vol. 108, pp. 286- 291 ,(2006) , 10.1182/BLOOD-2005-10-3969
Martin Hoyle, Gabriel Rogers, Tiffany Moxham, Zulian Liu, Ken Stein, Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia Value in Health. ,vol. 14, pp. 1057- 1067 ,(2011) , 10.1016/J.JVAL.2011.07.006
Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, Saengsuree Jootar, Jerzy Holowiecki, Nelson Hamerschlak, Timothy Hughes, Eric Bleickardt, David Dejardin, Jorge Cortes, Neil P. Shah, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. ,vol. 115, pp. 4136- 4147 ,(2009) , 10.1002/CNCR.24504